The aim of our work is to acquaint other fellow physicians with our experience in prescribing high doses of ALA to which there was only a therapeutic response in terms of significant reduction of neuropathic ailments in our patients. We continued the therapy for six months after the introduction, because the difficulties are still maintained, now in a very mild form. COVID-19 disease caused by the SARS-CoV-2 virus was first described in December 2019 in Wuhan, China, but has since spread rapidly globally. Although the number of cases and deaths has attracted a lot of media attention, less attention is paid to the long-term tribute taken by those who survived the disease Since the discovery, there have been more and more reports linking SARSCoV-2 infection to various nervous system disorders. These disorders can be broken down into processes that affect the brain and spinal cord that make up the central nervous system or CNS, as well as those that affect the peripheral nervous system or PNS. Every day we learn more about the spectrum of neuromuscular disorders that develop after COVID-19 disease. We present two patients with polyneuropathy after proven SARSCoV-2 virus infection, aged 37 and 45, without previous chronic diseases that may be associated with peripheral nerve damage. The dominant symptoms in both patients are weakness and unpleasant sensations in the hands and feet, fatigue and general weakness. Therapy with high doses of alpha-lipoic acid has led to a significant reduction in discomfort and improved quality of life of patients.